Current problems and future aspects of pharmacovigilance in India

International Journal of Pharma and Bio Sciences

Volumn 2, Issue 1, 2011, Pages 15-28

  Ghosh, A K ^a   De, A ^b   Bala, N N ^b  

^a SIKKIM UNIVERSITY   (India)

^b BCDA College of Pharmacy and Technology   (India)

Author keywords

Adverse drug reactions; Drug safety; Paradoxical reaction; Pharmacovigilance; Polypharmacy; Public health programme

Indexed keywords

ACETYLSALICYLIC ACID; AMPHETAMINE; ANESTHETIC AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BCG VACCINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DIAZEPAM; EPHEDRINE; GENTAMICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERFERON; ISOTRETINOIN; METFORMIN; METHYLPHENIDATE; MISOPROSTOL; MORPHINE; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; POLIOMYELITIS VACCINE; PROPOFOL; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SILDENAFIL; STAVUDINE; TETRAHYDROLIPSTATIN; THALIDOMIDE; UNINDEXED DRUG;

ANEMIA; ARTICLE; BIRTH DEFECT; CARDIOVASCULAR DISEASE; CHLOASMA; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DROWSINESS; DRUG DEPENDENCE; DRUG FATALITY; DRUG SURVEILLANCE PROGRAM; ERECTILE DYSFUNCTION; FEVER; FUNDING; GLAUCOMA; HAIR LOSS; HEADACHE; HEALTH CARE COST; HEARING IMPAIRMENT; HEART INFARCTION; HUMAN; HYPERTENSION; IATROGENIC DISEASE; INCREASED APPETITE; INDIA; INSOMNIA; INTESTINAL BLEEDING; KIDNEY FAILURE; LACTIC ACIDOSIS; LIVER INJURY; PATIENT ASSESSMENT; PATIENT SELECTION; PERIPHERAL NEUROPATHY; POLYPHARMACY; POSTMARKETING SURVEILLANCE; PUBLIC HEALTH; RHABDOMYOLYSIS; SPONTANEOUS ABORTION; STROKE; THROMBOSIS;

EID: 84855307849     PISSN: None     EISSN: 09756299     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Tripathi KD. Essentials of Medical Pharmacology. 5th Edn, Jaypee Brothers Medical Publishers (P) Ltd.: 202-203, (2003).
2. Rang HP, Dale MM, Ritter JM, Moore PK. Pharmacology. 5th Edn, Elservier: 122-123, (2006).
3. J. R. Nebeker Clarifying Adverse Drug Events: A Clinician's Guide to Terminology, Documentation and Reporting. Ann Intern Med, 140:795-801, (2004).
4. J. R. Nebeker, P. Barach, M. H. Samore. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann. Intern. Med., 140 (10): 795- 801, (2004).
5. M. M. Fulton, E. R. Allen Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract, 17:123-132, (2005).
6. B. Starfield. Is US health really the best in the world?. JAMA, 284 (4): 483-485, (2000).
7. Benzodiazepines: Paradoxical Reactions & Long-Term Side-Effects
8. Expert Working Group (Efficacy) of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (2007)
9. The Importance of Pharmacovigilance, WHO 2002
10. WHO Technical Report No 498 (1972)
11. The importance of pharmacovigilance; safety monitoring of medical products, geneva, World Health Organization, 2002
12. R. Mann, E. Andrews, eds, pharmacovigilance, chichester, wiley & sons, 2002.
13. Safety monitoring of medical products WHO Guidelines for setting up and running a pharmacovigilance centre, stora Target 3, Uppsala, Sweden, The Uppsala Monitoring Centre, 2000
14. S. Shaker PEM in the UK and Coulter D. PEM in New Zealand in Mann R. Andrews E. eds. Pharmacovigilance, chichester, wiley & sons, 333-362, (2002).
15. P. Biswas, A. K. Biswas Setting standards for proactive pharmacovigilance in India: The way forward. Indian J Pharmacol,39:124-128, (2007).
16. S. Prakash Pharmacovigilance in India. Indian J Pharmacol, 39:123, (2007)
17. Rang HP, Dale MM, Ritter JM, Moore PK. Pharmacology. 5th Edn, Elservier: 146, (2006).
18. "Clinical Drug Use". http://www.clinicaldruguse.com/. Retrieved 2007-09-18. 19
19. K. A. Phillips, D. L. Veenstra, E. Oren et. al. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA, 286 (18):2270-2279 (2001).
20. D. B. Goldstein. Pharmacogenetics in the laboratory and the clinic. N. Engl. J. Med.,348 (6): 553-556, (2003).
21. "Drug-Interactions.com". http://medicine.iupui.edu/flockhart/. Retrieved 2007-09-18.
22. Weinshilboum R (2003). "Inheritance and drug response. N. Engl. J. Med., 348 (6): 529-537, (2003).
23. W. E. Evans, H. L. McLeod "Pharmacogenomics-drug disposition, drug targets, and side effects. N. Engl. J. Med., 348 (6): 538-549, (2003).
24. C. L. DeVane. Clinical significance of drug binding, protein binding, and binding displacement drug interactions. Psychopharmacology bulletin, 36 (3): 5-21, (2002).
25. L. Z. Benet, B. A. Hoener. Changes in plasma protein binding have little clinical relevance. Clin. Pharmacol. Ther, 71 (3): 115-121, (2002).
26. C. D. Sands, E. S. Chan, T. E. Welty. Revisiting the significance of warfarin protein-binding displacement interactions. The Annals of pharmacotherapy, 36 (10): 1642-1644, (2002).
27. M. Aoun, C. Jacquy, L. Debusscher, et al. Peripheral neuropathy associated with fluoroquinolones. Lancet, 340, (1992).
28. J. S. Cohen. Peripheral neuropathy associated with fluoroquinolones. Ann Pharmacother, 35 (12): 1540-1547, (2001).
29. K. Hedenmalm, O. Spigset. Peripheral sensory disturbances related to treatment with fluoroquinolones. J. Antimicrob. Chemother, 37 (4): 831-837, (1996).
30. J. T. Jagose, D. R. McGregor, G. R. Nind. Achilles tendon ruptures due to ciprofloxacin. N. Z. Med. J., 109 (1035): 471-472, (1996).
31. J. M. Casparian, M. Luchi, R. E. Moffat et. al. "Quinolones and tendon ruptures". South. Med. J., 93 (5): 488-491, (2000).
32. S. I. Haider, K. Johnell, G. R. Weitoft, et. al. The influence of educational level on polypharmacy and inappropriate drug use: a register-based study of more than 600,000 older People. Journal of the American Geriatrics Society, 57 (1): 62- 69, (2009).
33. S. I. Haider, K. Johnell, M. Thorslund, et. al. Trends in polypharmacy and potential drug- drug interactions across educational groups in elderly patients in Sweden for the period 1992 - 2002. International Journal of Clinical Pharmacology and Therapeutics, 45 (12): 643-653, (2007).
34. C. M. Boyd, J. Darer, C. Boult, et. al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA, 294 (6): 716- 724, (2005).
35. S. I. Haider, K. Johnell, M. Thorslund, et. al. Analysis of the association between polypharmacy and socioeconomic position among elderly aged >/=77 years in Sweden. Clin Ther, 32 (2): 419-427, (2007).
36. A. J. Mandell, K. A. Selz, Dynamical systems in psychiatry: Now what? Biological Psychiatry, 32: 299-301, (1992).
37. S. P. Fisher-Hoch. Lessons fromnosocomial viral haemorrhagic fever outbreaks. Br. Med. Bull., 73-74: 123- 137, (2005).
38. N. P. Spanos Multiple Identities & False Memories: A Sociocognitive Perspective. American Psychological Association (APA). ISBN 1-55798-340-2., (1996).
39. J. R. Pruett, R. John. L. J. Luby. Recent Advances in Prepubertal Mood Disorders: Phenomenology and Treatment. Curr Opin Psychiatry, 17 (1): 31-36, (2004).
40. B. G. Braun, B.G. Dissociation:, Vol. 2, No. 2, p. 066-069, (1989).
41. N. M. Hadler. Fibromyalgia, chronic fatigue, and other iatrogenic diagnostic algorithms. Do some labels escalate illness in vulnerable patients?. Postgrad Med, 102 (6): 43, (1997).
42. S. E. Abbey. Somatization, illness attribution and the sociocultural psychiatry of chronic fatigue syndrome. Ciba Found Symp, 173: 238-252, (1993).
43. J. A. Boscarino. Evaluation of the Iatrogenic Effects of Studying Persons Recently Exposed to a Mass Urban Disaster. (2004).
44. R. H. Moos. Iatrogenic effects of psychosocial interventions for substance use disorders: prevalence, predictors, prevention. Addiction, 100 (5): 595-604, (2005).
45. B. Weiss, A. Caron, S. Ball, et. al. Iatrogenic effects of group treatment for antisocial youths. Journal of Consulting and Clinical Psychology, 73 (6): 1036-1044, (2005).
46. K. Kouyanou, C. E. Pither, S. Wessely. Iatrogenic factors and chronic pain. Psychosomatic Medicine, 59 (6): 597-604, (1997).
47. B. Meessen, Z. Zhenzhong, W. Van Damme, et. al.. Iatrogenic poverty. Tropical Medicine & International Health, 8 (7): 581- 584, (2007).
48. D. B. Evans, G. Carrin, A. M. Aguilar-Rivera, et. al..Protecting Households from Catastrophic Health Spending. Health Affairs, 26 (4): 972-983, (2007).
49. E. Goldmann, S. Galea. Borrowing And Selling To Pay For Health Care In Low-And Middle-Income Countries. Health Affairs, 28 (4): 10056-10066, (2009).
50. K. Steel, P. M. Gertman, C. Crescenzi, et. al. Iatrogenic illness on a general medical service at a university hospital. N. Engl. J. Med., 304 (11): 638-642, (1981).
51. S. N. Weingart, A. N. Ship, M. D. Aronson. Confidential clinician-reported surveillance of adverse events among medical inpatients. J Gen Intern Med, 15 (7): 470-477, (2000).
52. J. G. Bramness, S. Skurtveit, J. Mørland. Flunitrazepam: psychomotor impairment, agitation and paradoxical reactions. Forensic Sci. Int., 159 (2-3): 83-91, (2006).
53. J. O. Cole, J. C. Kando. Adverse behavioral events reported in patients taking alprazolam and other benzodiazepines. The Journal of clinical psychiatry., 54 (Suppl:49-61): 62-63, (1993).
54. M. E. Berman, G. D. Jones, M. S. McCloskey. The effects of diazepam on human self-aggressive behavior. Psychopharmacology (Berl.), 178 (1): 100-106,(2005).
55. Paradoxical Reactions to Benzodiazepines
56. Letter: Tranquilizers causing aggression. British medical journal., 1 (5952): 266, (1975).
57. R. Perlwitz, E. Grimmberger, R. Schmidtsdorf. Immediate effect of intravenous clonazepam on the EEG. Psychiatr Neurol Med Psychol (Leipz), 1980, 32 (6): 338-344, (1995).
58. J. L. Senninger, M. Laxenaire. Violent paradoxal reactions secondary to the useof benzodiazepines]. Annales médicopsychologiques., 153 (4): 278-281, (1995).
59. Chlorpromazine - Adverse Effects-Behavioral Reactions
60. M. H. Teicher, C. Glod, J. O. Cole. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry, 147 (2): 207-210, (1990).
61. R. A. King, M. A. Riddle, P. B. Chappell, et. al. "Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment". J Am Acad Child Adolesc Psychiatry, 30 (2): 179-186, (1991).
62. Pharmaceutical Microbiology, pp188, 7th Edition, Denyer, Hodges, Gorman
63. Expert working group (efficacy) of the international conference on harmonization of technical requirements for registration of pharmaceuticals for human use. (2007).
64. J. P. Ioannidis, J Lau. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA, 285(4): 437-443, (2001).
65. R. Chou, M. Helfand. Challenges in systematic reviews that assess treatment harms. Ann Intern Med, 142(12 Pt 2): 1090-2000, (2005).
66. J. P. Ioannidis, S. J. Evans, P. C. Gøtzsche, et. al. "Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med, 141(10): 781-788, (2004).
67. Protocol for National pharmacovigilance program, CDSCO, Ministry of Health and family welfare, government of India, November 2004
68. S. K. Gupta, Agarwal Rence, Ensuring drug safety.
69. M. D. Nair Pharmacovigilance: the need for a formal system in India, available from http://www.pharmabij.com
70. J. Lazarou, B. H. Pomeranz, P. N. Corey Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA, 279:1200-1205, (1998).
71. T. K. Gandhi, S. N. Weigngart, J. Borus, et. al. Adverse drug events in ambulatory care. N Engl J Med, 348:1556-1564, (2003).
72. G. Duff, M. Kendall, Dr J. Raine, et. al. Henderson Current problems in pharmacovigilance commission on human medicines, MHRA, UK. 31:1-12, (2006).
73. MHRA/CSM Current Problems in Pharmacovigilance. 30:1-2, (2004).
74. MCA/CSM Current Problems in Pharmacovigilance. 24: 5, (1998).
75. MCA/CSM Current Problems in Pharmacovigilance. 28: 7, (2002).
76. MCA/CSM Current Problems in Pharmacovigilance. 29: 5, (2003).
77. BTS/SIGN. Management of Asthma. Thorax, 54:1-94, (2003).
78. Krantz MJ, et al. Ann. Intern. Med., 137: 501-504, (2002).
79. Chang, D.F. & Campbell, J.R. J Cataract Refract Surg 31: 664-673, (2005).
80. Grant R.Wilkinson. N. Engl J Med, 352: 2211-2221, (2005).
81. Wayne A.Ray et al. N. Engl J Med, 351: 1089-1096, (2004).
82. Hawton K et al. British Medical Journal, 326: 1006-1008, (2003).
83. The Erice Declaration on Communicating Information. Drug Safety, Sept 27, (1997).
84. Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal of the European Union 30 April 2004: L136/34-L 136/57.